{
    "clinical_study": {
        "@rank": "127588", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo Control"
            }, 
            {
                "arm_group_label": "Benzonatate", 
                "arm_group_type": "Experimental", 
                "description": "Benzonatate Active"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a single-center, randomized, third party blind, placebo controlled, dose escalation\n      study of benzonatate following single dose administration. The primary oobjective is to\n      assess the safety and tolerability of increasing oral doses of benzonatate following single\n      dose administration in healthy male and female subjects."
        }, 
        "brief_title": "Benzonatate Dose Tolerance Study", 
        "completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "condition": "Cough", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.\n             Healthy is defined as no clinically relevant abnormalities identified by a detailed\n             medical history, full physical examination, including blood pressure and pulse rate\n             measurement, 12 lead ECG, or clinical laboratory tests.\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease (including drug allergies, but excluding untreated, asymptomatic,\n             seasonal allergies at the time of dosing).\n\n        Any other severe acute or chronic medical or psychiatric condition or laboratory\n        abnormality that may increase the risk associated with study participation or\n        investigational product administration or may interfere with the interpretation of study\n        results, and in the judgment of the investigator, would make the subject inappropriate for\n        entry into this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "9", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01690975", 
            "org_study_id": "B3551001", 
            "secondary_id": "BT-10-29"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo - single dose at start of each treatment period", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Benzonatate", 
                "description": "Benzonatate - 400 mg single dose", 
                "intervention_name": "Benzonatate - 400 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Benzonatate", 
                "description": "Benzonatate - 600 mg single dose", 
                "intervention_name": "Benzonatate - 600 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Benzonatate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 19, 2012", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3551001&StudyName=Benzonatate%20Dose%20Tolerance%20Study"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Tolerability of Benzonatate Following Single Dose Administration in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose"
            }, 
            {
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01690975"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Maximum tolerated dose (MTD): Assessed at end of study", 
            "safety_issue": "No", 
            "time_frame": "End of study (2 months)"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}